USO 24105
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer (CAAA617A12402)
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
Signed informed consent must be obtained prior to participation in the study
Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
For more information on this trial CLICK HERE .
Available at: